Our Beginning
May 1991
Myriad Genetics, Inc. is founded, making it one of the first genomics companies in history.
Our Beginning
First Gene Discovery
Fall 1993
Myriad announces the discovery of the P16 gene that is associated with hereditary melanoma.
BRCA1 Discovery
September 1994
Myriad scientists publish in Science the discovery of the BRCA1 gene that is associated with hereditary breast and ovarian cancer.
Public Company
October 1995
Myriad becomes a public company and is traded on NASDAQ under the ticker: MYGN.
BRCA2 Discovery
December 1995
Myriad announces the discovery of the BRCA2 gene that is associated with hereditary breast and ovarian cancer.
BRACAnalysis ® Launches
November 1996
Myriad launches BRACAnalysis®, the first full length gene sequencing test for a major, common disease, for the oncology market.
DEP1 Discovery
February 2003
Myriad announces the discovery of major depression gene DEP1 in collaboration with Abbott Laboratories.
Preventative BRACAnalysis ® Launches
January 2008
Myriad launches BRACAnalysis® for the women’s health preventative care market, significantly expanding access to genetic cancer testing.
Prolaris® Launches
March 2010
Myriad launched Prolaris®, the first ever prognostic test to predict prostate cancer survival.
PARP Companion Diagnostics
2011
Myriad enters into three companion diagnostic collaborations for PARP inhibitors used in patients with ovarian cancer.
One-Million Milestone
February 2013
The one-millionth patient is tested with BRACAnalysis® test.
myRisk® Launches
September 2013
Myriad launches Myriad myRisk® Hereditary Cancer, a multi-gene panel test for eight hereditary cancers.
BRACAnalysis CDx® Receives FDA Approval
December 2014
Myriad receives FDA approval for its BRACAnalysis CDx® test to identify ovarian cancer patients who may benefit from the PARP inhibitor Lynparza™ (olaparib).
Expansion into Mental Health
August 2016
Myriad acquires Assurex Health and the GeneSight® genetic test for several mental health conditions.
EndoPredict® Launches
March 2017
EndoPredict® test is launched in the United States, providing three separate results to optimize treatment for patients with breast cancer.
riskScore® Launches
September 2017
Myriad launches riskScore® test, providing eligible women with a comprehensive, personalized breast cancer risk assessment.
BRACAnalysis CDx® Companion Diagnostic
January 2018
Myriad receives FDA approval for BRACAnalysis CDx® as a companion diagnostic for Lynparza™ in patients with metastatic breast cancer.
Expansion into Reproductive Health
July 2018
Myriad acquires Counsyl and enters the reproductive genetic testing market.
riskScore® Validation in Additional Ancestries
December 2018
Myriad validates first ever polygenic score to predict breast cancer risk in women of Hispanic ancestry
Paul Diaz Named CEO
August 2020
Paul J. Diaz appointed President and Chief Executive Officer of Myriad Genetics.
Helping More Patients
March 2021
Myriad Genetics joins forces with Intermountain Precision Genomics for a comprehensive offering of germline and somatic tumor testing services.